Vanda Pharmaceuticals (NASDAQ:VNDA) Lifted to “Buy” at StockNews.com

Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Sunday.

Separately, TheStreet cut shares of Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a report on Thursday, February 8th.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA opened at $4.12 on Friday. Vanda Pharmaceuticals has a fifty-two week low of $3.30 and a fifty-two week high of $7.00. The stock has a market capitalization of $237.06 million, a P/E ratio of 82.42 and a beta of 0.76. The company’s 50-day simple moving average is $4.15 and its 200-day simple moving average is $4.06.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. Vanda Pharmaceuticals had a net margin of 1.30% and a return on equity of 0.46%. The business had revenue of $45.27 million for the quarter, compared to analysts’ expectations of $37.00 million. On average, research analysts forecast that Vanda Pharmaceuticals will post -0.06 EPS for the current year.

Institutional Trading of Vanda Pharmaceuticals

Several large investors have recently bought and sold shares of VNDA. BlackRock Inc. lifted its stake in Vanda Pharmaceuticals by 7.0% during the 2nd quarter. BlackRock Inc. now owns 10,810,016 shares of the biopharmaceutical company’s stock valued at $71,238,000 after acquiring an additional 711,086 shares during the period. State Street Corp lifted its stake in shares of Vanda Pharmaceuticals by 22.1% in the 1st quarter. State Street Corp now owns 4,551,912 shares of the biopharmaceutical company’s stock valued at $30,907,000 after purchasing an additional 824,114 shares during the period. Vanguard Group Inc. lifted its stake in shares of Vanda Pharmaceuticals by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 3,894,554 shares of the biopharmaceutical company’s stock valued at $38,478,000 after purchasing an additional 56,822 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Vanda Pharmaceuticals by 1.6% in the 1st quarter. Renaissance Technologies LLC now owns 2,935,225 shares of the biopharmaceutical company’s stock valued at $19,930,000 after purchasing an additional 45,800 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Vanda Pharmaceuticals by 11.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,263,159 shares of the biopharmaceutical company’s stock valued at $25,597,000 after purchasing an additional 229,581 shares during the period. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.